(HROW) Harrow Health - Ratings and Ratios

Harrow, Inc. is a specialized eyecare pharmaceutical company with a strong focus on innovation and patient outcomes. They specialize in the development, manufacturing, and distribution of ophthalmic medications, catering to a wide range of eye conditions. Their product portfolio is both broad and deep, addressing everything from inflammation and infection to surgical recovery and chronic eye diseases.

The companys flagship offering is ImprimisRx, a compounding pharmacy that provides customized ophthalmic medications. This service is particularly valuable for patients who require tailored treatments not widely available on the market. Beyond compounding, Harrow has built a robust portfolio of branded products. For instance, IHEEZO is a fast-acting local anesthetic used in cataract surgery, while ILEVRO targets ocular inflammation post-surgery. Their MAXITROL and VIGAMOX products are well-established treatments for bacterial conjunctivitis and uveitis.

Financially, Harrow operates with a market capitalization of approximately $1.136 billion, reflecting its established presence in the eyecare market. The companys price-to-sales ratio of 6.72 indicates a premium valuation, likely due to its strong revenue growth and profitability margins. Investors should note the companys price-to-book ratio of 19.60, suggesting high expectations for future growth relative to its current asset base.

Harrow has also made strategic moves to enhance its market position. Their collaboration with Asembia focuses on improving both provider and patient experiences through digital platforms and hub services. This partnership underscores Harrows commitment to modernizing eyecare delivery and improving patient access to essential medications.

In September 2023, the company rebranded from Harrow Health, Inc. to Harrow, Inc., signaling a streamlined focus on its core eyecare business. This rebranding aligns with its strategic objective of becoming a leader in the ophthalmic